{"id":350518,"date":"2026-11-17T15:02:34","date_gmt":"2026-11-17T09:32:34","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=350518"},"modified":"2026-11-17T15:02:34","modified_gmt":"2026-11-17T09:32:34","slug":"generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/","title":{"rendered":"3 Generic Medicines Maker, Document Workflow Software Provider and Grinding Wheels and Abrasives Maker Stocks With a Strong Future Roadmap: Strides Pharma Science, Newgen Software Technologies and Grindwell Norton"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E84;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Strides Pharma Science, Newgen Software Technologies and Grindwell Norton: ROE of 16.4% to 18.7% and FY22 to FY26 revenue CAGR of 11.3% to 19.4%. Prices as of 16 Nov 2026.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E84;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The three <strong>pharma, workflow software and abrasives stocks<\/strong> to watch are <strong>Strides Pharma Science<\/strong>, <strong>Newgen Software Technologies<\/strong> and <strong>Grindwell Norton<\/strong>. Their <strong>return on equity<\/strong> ranges from <strong>16.4% to 18.7%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 11.3% to 19.4%. Newgen Software Technologies leads on both return on equity at 18.7% and revenue growth at 19.4% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.<\/p>\n<\/div>\n<p>Pharma, workflow software and abrasives stocks bring together companies with a visible plan for the years ahead. Strides Pharma Science, Newgen Software Technologies and Grindwell Norton cover a pharmaceuticals company, a workflow software company and an abrasives maker.<\/p>\n<p>This list covers three pharma, workflow software and abrasives stocks with complete current figures: Strides Pharma Science, Newgen Software Technologies and Grindwell Norton. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#What_Are_Pharma_Workflow_Software_and_Abrasives_Stocks\" title=\"What Are Pharma, Workflow Software and Abrasives Stocks?\">What Are Pharma, Workflow Software and Abrasives Stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#Pharma_Workflow_Software_and_Abrasives_Stocks_at_a_Glance\" title=\"Pharma, Workflow Software and Abrasives Stocks at a Glance\">Pharma, Workflow Software and Abrasives Stocks at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#Why_Do_Pharma_Workflow_Software_and_Abrasives_Stocks_Have_a_Strong_Roadmap_in_India\" title=\"Why Do Pharma, Workflow Software and Abrasives Stocks Have a Strong Roadmap in India?\">Why Do Pharma, Workflow Software and Abrasives Stocks Have a Strong Roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#Why_Strides_Pharma_Science_Features_Among_These_Pharma_Workflow_Software_and_Abrasives_Stocks\" title=\"Why Strides Pharma Science Features Among These Pharma, Workflow Software and Abrasives Stocks\">Why Strides Pharma Science Features Among These Pharma, Workflow Software and Abrasives Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#Why_Newgen_Software_Technologies_Features_Among_These_Pharma_Workflow_Software_and_Abrasives_Stocks\" title=\"Why Newgen Software Technologies Features Among These Pharma, Workflow Software and Abrasives Stocks\">Why Newgen Software Technologies Features Among These Pharma, Workflow Software and Abrasives Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#Why_Grindwell_Norton_Features_Among_These_Pharma_Workflow_Software_and_Abrasives_Stocks\" title=\"Why Grindwell Norton Features Among These Pharma, Workflow Software and Abrasives Stocks\">Why Grindwell Norton Features Among These Pharma, Workflow Software and Abrasives Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#Strides_Pharma_Science_vs_Newgen_Software_Technologies_vs_Grindwell_Norton_on_Key_Financials\" title=\"Strides Pharma Science vs Newgen Software Technologies vs Grindwell Norton on Key Financials\">Strides Pharma Science vs Newgen Software Technologies vs Grindwell Norton on Key Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#Key_Risks_to_Check_Before_Investing_in_Pharma_Workflow_Software_and_Abrasives_Stocks\" title=\"Key Risks to Check Before Investing in Pharma, Workflow Software and Abrasives Stocks\">Key Risks to Check Before Investing in Pharma, Workflow Software and Abrasives Stocks<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#Final_Thoughts_on_Pharma_Workflow_Software_and_Abrasives_Stocks\" title=\"Final Thoughts on Pharma, Workflow Software and Abrasives Stocks\">Final Thoughts on Pharma, Workflow Software and Abrasives Stocks<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#What_are_pharma_workflow_software_and_abrasives_stocks\" title=\"What are pharma, workflow software and abrasives stocks?\">What are pharma, workflow software and abrasives stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#Which_pharma_workflow_software_and_abrasives_stocks_are_covered_in_this_list\" title=\"Which pharma, workflow software and abrasives stocks are covered in this list?\">Which pharma, workflow software and abrasives stocks are covered in this list?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#Why_do_pharma_workflow_software_and_abrasives_stocks_have_a_strong_future_roadmap_in_India\" title=\"Why do pharma, workflow software and abrasives stocks have a strong future roadmap in India?\">Why do pharma, workflow software and abrasives stocks have a strong future roadmap in India?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#How_has_Strides_Pharma_Science_performed_financially\" title=\"How has Strides Pharma Science performed financially?\">How has Strides Pharma Science performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#How_has_Newgen_Software_Technologies_performed_financially\" title=\"How has Newgen Software Technologies performed financially?\">How has Newgen Software Technologies performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#How_has_Grindwell_Norton_performed_financially\" title=\"How has Grindwell Norton performed financially?\">How has Grindwell Norton performed financially?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#What_risks_should_investors_check_before_buying_pharma_workflow_software_and_abrasives_stocks\" title=\"What risks should investors check before buying pharma, workflow software and abrasives stocks?\">What risks should investors check before buying pharma, workflow software and abrasives stocks?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/generic-medicines-maker-document-workflow-software-provider-and-grinding-wheels-and-abrasives-maker-stocks-roadmap-tundra-list\/#Is_this_list_of_pharma_workflow_software_and_abrasives_stocks_investment_advice\" title=\"Is this list of pharma, workflow software and abrasives stocks investment advice?\">Is this list of pharma, workflow software and abrasives stocks investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Are_Pharma_Workflow_Software_and_Abrasives_Stocks\"><\/span><strong>What Are Pharma, Workflow Software and Abrasives Stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Pharma, workflow software and abrasives stocks<\/strong> are listed companies that make generic medicines for India and regulated markets, build software that helps banks and governments manage documents and workflows, and make grinding wheels, coated abrasives and ceramics for industry. Their earnings depend on medicine orders, software licences and factory activity.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Pharma_Workflow_Software_and_Abrasives_Stocks_at_a_Glance\"><\/span><strong>Pharma, Workflow Software and Abrasives Stocks at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">CMP (Rs)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Market Cap (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Industry P\/E<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">ROE (%)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">D\/E<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/star\/strides-pharma-science-ltd-share-price-today\">Strides Pharma Science<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">986.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">9,491<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">15.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">36.0<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.9<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.57<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/newgen\/newgen-software-technologies-ltd-share-price-today\">Newgen Software Technologies<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">433.3<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">6,835<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">21.8<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">17.5<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.02<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\"><a href=\"https:\/\/univest.in\/stocks\/grindwell\/grindwell-norton-ltd-share-price-today\">Grindwell Norton<\/a><\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,844.7<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">20,188<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">46.1<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">44.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">16.4<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">0.02<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>On valuation, Strides Pharma Science trades at a <strong>P\/E<\/strong> below the industry P\/E, while Newgen Software Technologies and Grindwell Norton trade above it, which reflects the growth the market already expects. Readers comparing pharma, workflow software and abrasives stocks should look at <strong>return on equity<\/strong> and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in pharma, workflow software and abrasives stocks can use the coming numbers to test whether growth is holding.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Do_Pharma_Workflow_Software_and_Abrasives_Stocks_Have_a_Strong_Roadmap_in_India\"><\/span><strong>Why Do Pharma, Workflow Software and Abrasives Stocks Have a Strong Roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Pharma, workflow software and abrasives stocks<\/strong> have a strong roadmap in India because steady demand for medicines, rising use of workflow software and wider factory output keep widening the market for these companies.<\/p>\n<ul>\n<li><strong>Pharmaceuticals.<\/strong> Patients need reliable generic medicines.<\/li>\n<li><strong>Workflow software.<\/strong> Offices move to digital processes.<\/li>\n<li><strong>Abrasives.<\/strong> Factories use wheels for finishing parts.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Why_Strides_Pharma_Science_Features_Among_These_Pharma_Workflow_Software_and_Abrasives_Stocks\"><\/span><strong>Why Strides Pharma Science Features Among These Pharma, Workflow Software and Abrasives Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the pharma, workflow software and abrasives stocks on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.<\/p>\n<p>The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a <strong>market capitalisation<\/strong> of Rs 9,491 crore. The stock trades at a <strong>P\/E<\/strong> of 15.0, below the industry P\/E of 36.0.<\/p>\n<p>Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.<\/p>\n<p><strong>Roadmap:<\/strong> The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.<\/p>\n<p><strong>What to watch:<\/strong> Track new US launches and the pace of price erosion in generic categories.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Newgen_Software_Technologies_Features_Among_These_Pharma_Workflow_Software_and_Abrasives_Stocks\"><\/span><strong>Why Newgen Software Technologies Features Among These Pharma, Workflow Software and Abrasives Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the generic injectables, content software and grinding wheel shares on this list, Newgen Software Technologies, based in Delhi, offers low-code platforms for content management, process automation and customer engagement to banks, insurers and governments.<\/p>\n<p>Revenue rose from Rs 809 crore in FY22 to Rs 1,641 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 164 crore in FY22 to Rs 301 crore in FY26, which works out to a compound annual growth rate of 16.3%.<\/p>\n<p>In the June 2026 quarter, revenue grew 12.3% year on year to Rs 393 crore, while net profit rose 26.3% to Rs 62.8 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 6,835 crore. The stock trades at a P\/E of 21.8, above the industry P\/E of 17.5.<\/p>\n<p><strong>Roadmap:<\/strong> Digital transformation at banks and public sector organisations, plus new artificial intelligence features on its platform, widen its addressable market. A growing share of recurring licence and cloud revenue improves predictability.<\/p>\n<p><strong>What to watch:<\/strong> Monitor deal wins in the banking sector and the growth of recurring revenue.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Grindwell_Norton_Features_Among_These_Pharma_Workflow_Software_and_Abrasives_Stocks\"><\/span><strong>Why Grindwell Norton Features Among These Pharma, Workflow Software and Abrasives Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Among the three companies on this list, Grindwell Norton, a Saint-Gobain group company, makes abrasives, ceramics and plastics products, including grinding wheels, coated abrasives and silicon carbide.<\/p>\n<p>In the June 2026 quarter, revenue grew 13.8% year on year to Rs 828 crore, while net profit rose 22.1% to Rs 115 crore. Revenue rose from Rs 2,066 crore in FY22 to Rs 3,168 crore in FY26, a compound annual growth rate of 11.3%.<\/p>\n<p>Net profit grew from Rs 295 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 9.0%. The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 20,188 crore. The stock trades at a P\/E of 46.1, above the industry P\/E of 44.4.<\/p>\n<p><strong>Roadmap:<\/strong> Demand from automobiles, steel, infrastructure and general manufacturing supports its core abrasives range, while ceramics and plastics offer higher-value niches. The group&#8217;s technology support and a debt-free balance sheet allow it to add capacity at its own pace.<\/p>\n<p><strong>What to watch:<\/strong> Keep tabs on industrial activity and input costs for raw materials such as silicon carbide.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Strides_Pharma_Science_vs_Newgen_Software_Technologies_vs_Grindwell_Norton_on_Key_Financials\"><\/span><strong>Strides Pharma Science vs Newgen Software Technologies vs Grindwell Norton on Key Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The table below sets the three pharma, workflow software and abrasives stocks side by side on revenue, profit and margin, using reported figures.<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY22 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Revenue CAGR (FY22-FY26)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Profit (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">FY26 Net Margin<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Strides Pharma Science<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,202<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">5,009<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.8%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">575<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Newgen Software Technologies<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">809<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,641<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">19.4%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">301<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">18.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Grindwell Norton<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">2,066<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">3,168<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">11.3%<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">417<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.2%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p>Newgen Software Technologies posts the highest return on equity in this group at 18.7%. Strides Pharma Science has the largest FY26 revenue at Rs 5,009 crore, and Newgen Software Technologies shows the fastest revenue growth with a 19.4% compound annual rate. A useful habit with <strong>pharma, workflow software and abrasives stocks<\/strong> is to check each new quarterly result against the capacity plans the company described earlier.<\/p>\n<p>The June 2026 quarter, the latest reported, gives a fresh read on momentum:<\/p>\n<div style=\"overflow-x:auto;\">\n<table style=\"border-collapse:collapse;width:100%;\">\n<thead>\n<tr>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Company<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY26 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Q1 FY27 Revenue (Rs Cr)<\/th>\n<th style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;background:#F0F4F8;\">Year-on-Year Growth<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Strides Pharma Science<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,128<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">1,270<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Newgen Software Technologies<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">350<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">393<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">12.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">Grindwell Norton<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">727<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">828<\/td>\n<td style=\"border:1px solid #DDDDDD;padding:8px 10px;text-align:left;\">13.8%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_to_Check_Before_Investing_in_Pharma_Workflow_Software_and_Abrasives_Stocks\"><\/span><strong>Key Risks to Check Before Investing in Pharma, Workflow Software and Abrasives Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Every theme carries risks that deserve a check before any decision. For these pharma, workflow software and abrasives stocks, the main points are: Long-term generic injectables, content software and grinding wheel shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.<\/p>\n<ul>\n<li><strong>Regulatory approvals.<\/strong> Plant inspections and approvals can affect supplies.<\/li>\n<li><strong>Client spending.<\/strong> Technology budgets can vary with global conditions.<\/li>\n<li><strong>Demand cycles.<\/strong> Sales can vary with seasons and rates.<\/li>\n<\/ul>\n<p>Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Use the Univest Stock Screener<\/a><\/strong> to filter pharma, workflow software and abrasives stocks by market capitalisation, P\/E, ROE and growth, and build your own shortlist.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Pharma_Workflow_Software_and_Abrasives_Stocks\"><\/span><strong>Final Thoughts on Pharma, Workflow Software and Abrasives Stocks<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><strong>Pharma, workflow software and abrasives stocks<\/strong> suit investors who prefer to study business strength before price moves. Strides Pharma Science, Newgen Software Technologies and Grindwell Norton each have a clear plan to grow. Based on the 16 November 2026 close, Strides Pharma Science trades at Rs 986.1, Newgen Software Technologies at Rs 433.3 and Grindwell Norton at Rs 1,844.7. Valuation matters as much as growth, so compare each company&#8217;s P\/E with its industry P\/E before adding any of these pharma, workflow software and abrasives stocks to a watchlist.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track pharma, workflow software and abrasives stocks, set price alerts and get research-backed stock ideas.<\/em><\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h3><span class=\"ez-toc-section\" id=\"What_are_pharma_workflow_software_and_abrasives_stocks\"><\/span><strong>What are pharma, workflow software and abrasives stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Pharma, workflow software and abrasives stocks are listed companies that make generic medicines for India and regulated markets, build software that helps banks and governments manage documents and workflows, and make grinding wheels, coated abrasives and ceramics for industry. Their earnings depend on medicine orders, software licences and factory activity. This list looks at three of them, Strides Pharma Science, Newgen Software Technologies and Grindwell Norton, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Which_pharma_workflow_software_and_abrasives_stocks_are_covered_in_this_list\"><\/span><strong>Which pharma, workflow software and abrasives stocks are covered in this list?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> This list covers Strides Pharma Science, Newgen Software Technologies and Grindwell Norton. Based on the 16 November 2026 close, Strides Pharma Science traded at Rs 986.1, Newgen Software Technologies at Rs 433.3 and Grindwell Norton at Rs 1,844.7. Their return on equity ranges from <strong>16.4% to 18.7%<\/strong>, and their <strong>revenue compound annual growth<\/strong> from FY22 to FY26 ranges from 11.3% to 19.4%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_do_pharma_workflow_software_and_abrasives_stocks_have_a_strong_future_roadmap_in_India\"><\/span><strong>Why do pharma, workflow software and abrasives stocks have a strong future roadmap in India?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> <strong>Pharma, workflow software and abrasives stocks<\/strong> have a strong roadmap in India because steady demand for medicines, rising use of workflow software and wider factory output keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need reliable generic medicines. Workflow software. Offices move to digital processes. Abrasives. Factories use wheels for finishing parts. Together these factors give the companies on this list a visible path for growth over the coming years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Strides_Pharma_Science_performed_financially\"><\/span><strong>How has Strides Pharma Science performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P\/E of 15.0, below the industry P\/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Newgen_Software_Technologies_performed_financially\"><\/span><strong>How has Newgen Software Technologies performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 809 crore in FY22 to Rs 1,641 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 164 crore in FY22 to Rs 301 crore in FY26, which works out to a compound annual growth rate of 16.3%. In the June 2026 quarter, revenue grew 12.3% year on year to Rs 393 crore, while net profit rose 26.3% to Rs 62.8 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 6,835 crore. The stock trades at a P\/E of 21.8, above the industry P\/E of 17.5. Looking ahead, digital transformation at banks and public sector organisations, plus new artificial intelligence features on its platform, widen its addressable market. A growing share of recurring licence and cloud revenue improves predictability.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_has_Grindwell_Norton_performed_financially\"><\/span><strong>How has Grindwell Norton performed financially?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Revenue rose from Rs 2,066 crore in FY22 to Rs 3,168 crore in FY26, a compound annual growth rate of 11.3%. Net profit grew from Rs 295 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 9.0%. In the June 2026 quarter, revenue grew 13.8% year on year to Rs 828 crore, while net profit rose 22.1% to Rs 115 crore. The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 20,188 crore. The stock trades at a P\/E of 46.1, above the industry P\/E of 44.4. Looking ahead, demand from automobiles, steel, infrastructure and general manufacturing supports its core abrasives range, while ceramics and plastics offer higher-value niches. The group&#8217;s technology support and a debt-free balance sheet allow it to add capacity at its own pace.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_risks_should_investors_check_before_buying_pharma_workflow_software_and_abrasives_stocks\"><\/span><strong>What risks should investors check before buying pharma, workflow software and abrasives stocks?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Investors should check a few risks before buying pharma, workflow software and abrasives stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Demand cycles. Sales can vary with seasons and rates. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_list_of_pharma_workflow_software_and_abrasives_stocks_investment_advice\"><\/span><strong>Is this list of pharma, workflow software and abrasives stocks investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What are pharma, workflow software and abrasives stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Pharma, workflow software and abrasives stocks are listed companies that make generic medicines for India and regulated markets, build software that helps banks and governments manage documents and workflows, and make grinding wheels, coated abrasives and ceramics for industry. Their earnings depend on medicine orders, software licences and factory activity. This list looks at three of them, Strides Pharma Science, Newgen Software Technologies and Grindwell Norton, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.\"}},{\"@type\":\"Question\",\"name\":\"Which pharma, workflow software and abrasives stocks are covered in this list?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"This list covers Strides Pharma Science, Newgen Software Technologies and Grindwell Norton. Based on the 16 November 2026 close, Strides Pharma Science traded at Rs 986.1, Newgen Software Technologies at Rs 433.3 and Grindwell Norton at Rs 1,844.7. Their return on equity ranges from 16.4% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.3% to 19.4%.\"}},{\"@type\":\"Question\",\"name\":\"Why do pharma, workflow software and abrasives stocks have a strong future roadmap in India?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Pharma, workflow software and abrasives stocks have a strong roadmap in India because steady demand for medicines, rising use of workflow software and wider factory output keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need reliable generic medicines. Workflow software. Offices move to digital processes. Abrasives. Factories use wheels for finishing parts. Together these factors give the companies on this list a visible path for growth over the coming years.\"}},{\"@type\":\"Question\",\"name\":\"How has Strides Pharma Science performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P\/E of 15.0, below the industry P\/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.\"}},{\"@type\":\"Question\",\"name\":\"How has Newgen Software Technologies performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 809 crore in FY22 to Rs 1,641 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 164 crore in FY22 to Rs 301 crore in FY26, which works out to a compound annual growth rate of 16.3%. In the June 2026 quarter, revenue grew 12.3% year on year to Rs 393 crore, while net profit rose 26.3% to Rs 62.8 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 6,835 crore. The stock trades at a P\/E of 21.8, above the industry P\/E of 17.5. Looking ahead, digital transformation at banks and public sector organisations, plus new artificial intelligence features on its platform, widen its addressable market. A growing share of recurring licence and cloud revenue improves predictability.\"}},{\"@type\":\"Question\",\"name\":\"How has Grindwell Norton performed financially?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Revenue rose from Rs 2,066 crore in FY22 to Rs 3,168 crore in FY26, a compound annual growth rate of 11.3%. Net profit grew from Rs 295 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 9.0%. In the June 2026 quarter, revenue grew 13.8% year on year to Rs 828 crore, while net profit rose 22.1% to Rs 115 crore. The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 20,188 crore. The stock trades at a P\/E of 46.1, above the industry P\/E of 44.4. Looking ahead, demand from automobiles, steel, infrastructure and general manufacturing supports its core abrasives range, while ceramics and plastics offer higher-value niches. The group's technology support and a debt-free balance sheet allow it to add capacity at its own pace.\"}},{\"@type\":\"Question\",\"name\":\"What risks should investors check before buying pharma, workflow software and abrasives stocks?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Investors should check a few risks before buying pharma, workflow software and abrasives stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Client spending. Technology budgets can vary with global conditions. Demand cycles. Sales can vary with seasons and rates. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.\"}},{\"@type\":\"Question\",\"name\":\"Is this list of pharma, workflow software and abrasives stocks investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pharma, Workflow Software and Abrasives Stocks with a strong future roadmap: Strides Pharma Science, Newgen Software Technologies and Grindwell Norton. Compare price, valuation, return on equity and revenue growth as of 16 November 2026.<\/p>\n","protected":false},"author":38,"featured_media":350517,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[3803,25131,25132,25130,13913,23488,13945,9049,25129],"class_list":["post-350518","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks","tag-best-stocks","tag-content-software-and-grinding-wheel-shares","tag-enterprise-software-and-industrial-abrasives-stocks","tag-generic-injectables","tag-grindwell-norton","tag-medicines","tag-newgen-software-technologies","tag-strides-pharma-science","tag-workflow-software-and-abrasives-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["350517"],"rank_math_title":["Pharma, Workflow Software and Abrasives Stocks"],"rank_math_description":["Compare 3 pharma, workflow software and abrasives stocks with a strong future roadmap on CMP, market cap, P\/E, ROE and revenue growth. Data as of 16 Nov 2026."],"rank_math_focus_keyword":["pharma, workflow software and abrasives stocks"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/11\/3-generic-medicines-maker-document-workflow-software-provider-and-grinding.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350518","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=350518"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350518\/revisions"}],"predecessor-version":[{"id":350519,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/350518\/revisions\/350519"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/350517"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=350518"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=350518"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=350518"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}